Exhaustion of cytotoxic effector systems may limit mAb-based immunotherapy in cancer patients()

The CD20 mAb ofatumumab (OFA) induces complement-mediated lysis of B cells. In an investigator-initiated phase II trial of OFA plus chemotherapy for chronic lymphocytic leukemia (CLL), OFA treatment promoted partial CLL B cell depletion which coincided with reduced complement titers. Remaining CLL B...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Beurskens, Frank J., Lindorfer, Margaret A., Farooqui, Mohammed, Beum, Paul V., Engelberts, Patrick, Mackus, Wendy J.M., Parren, Paul W.H.I., Wiestner, Adrian, Taylor, Ronald P.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3311731/
https://ncbi.nlm.nih.gov/pubmed/22368276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1103693
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items